SPOTLIGHT -
Tenofovir Disoproxil Fumarate Linked to Less HIV Metabolic, BMI Risk than Tenofovir Alafenamide
A new cohort assessment evidences a disparity in weight-related outcomes with the ART regimens at 18 months.
Read More
Tuberculosis Testing in New HIV Patients Does Not Effect ART Regimen
A comparative study of same-day and seven-day TB test results show there is little difference in HIV treatment adherence or outcomes at 48 weeks.
HTI Vaccine Regimen Shows Immunogenicity in HIV Patients
Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.
HIV CRISPR Screen Provides Novel Dependency Factors
New research from the Emerman Lab at Fred Hutchinson shows potential for advancing HIV-1 life cycle understanding.
Inflammation Could Help Predict HIV Women Cardiovascular Risks
Presented at CROI, investigators have identified sex-modified inflammatory predictors of cardiovascular and VTE risks among patients with HIV.
The Future Fight of HIV
A talk on optimistic, but pragmatic hopes for HIV cure and vaccine research, led by federal-level experts.
Chris Beyrer, MD, MPH: Evolving HIV Movements
Attention to the endemic virus has lessened over years, and screening and prevention access remains limited among the most at-risk groups.
The Current State of HIV in the United States
A John Hopkins expert and major study leader details the evolving epidemiology of the virus.
FDA Approves First Long-Acting Injectable Drug for HIV
The cabotegravir and rilpivirine formulation was approved on the basis of 2 trials assessing its viral suppression capability in 1100-plus adults with HIV.
First Case of Neisseria Gonorrhoeae Mosaic PenA60 Allele Identified in United States
The U.S. sentinel surveillance program is a project which monitors for antibiotic-resistant gonorrhea.
Can FDA-Approved MS Drug Block HIV Infection?
In testing, fingolimod blocked cell-free and cell-to-cell transmission of HIV, reducing latent virus.
Interferon-Stimulated Gene Inhibits HCV Replication
Study explores the antiviral mechanisms of C19orf66, an interferon-induced inhibitor.
Adolescent HIV Prevention: Overcoming the PrEP "Purview Paradox"
Conversations about PrEP with a clinician are the least common among adolescents with the greatest risk for HIV.
COVID-19 in People Living With HIV
A hospital case series of patients with both COVID-19 and HIV describes recovery, but highlights the need to refine treatment.
Acute Hepatitis C Infections Triple from 2009-2018
The CDC is calling for all adults to get tested for hepatitis C after the annual rate of infections tripled between 2009 and 2019.
CDC Issues New HCV Screening Recommendations
The 2 new recommendations are for HCV screening at least once for all adults aged 18 years or older and HCV screening for women during each pregnancy.
Examining HIV Training Pathways in Residency
HIV training pathways in residency have added 90 HIV physicians to the workforce since 2006.
Ending the HIV Epidemic Initiative: A Snapshot From the Trenches, 1 Year Later
Funded jurisdictions scramble to meet daunting deadlines yet maintain optimism that the new federal initiative can end flat funding and catalyze progress.
Prodrug Fostemsavir Lowers Viral HIV Levels
When drug resistance means ART options are exhausted, HIV patients need newer choices. A new study shows that novel prodrug fostemsavir is an effective alternative.
Living and Aging With HIV: Recognition and Management of Common Prescribing Pitfalls
With advancements in antiretroviral therapy, people with HIV are now living longer and developing age-related chronic conditions.
Safety Profiles of FDA-Approved PrEP Agents
PrEP Therapy for High-Risk HIV Candidates
Screening Recommendations for HIV and Risk Stratification
Burden of HIV in the USA and Associated Symptoms
Mycobacterium tuberculosis in Patients With HIV Carries Mortality Risk
Relying solely on blood tests means clinicians may miss cases of potentially deadly M tuberculosis—and waiting days to treat suspected cases could prove fatal.
Long-Acting ART, Islatravir, and Capsid Inhibitors
Ian Frank, MD, discusses upcoming treatments for people with HIV.
People Facing HIV Stigma Are Less Likely To Make Their Next Care Visit
Patients facing HIV stigma may encounter difficulties with retention in care.
George Hanna, MD: Islatravir Presentations at CROI 2020
George Hanna, MD, vice president and therapeutic head of infectious diseases at Merck Laboratories, discusses data from CROI 2020 on islatravir.
A Modeling Study Points the Way to Stopping HIV Spread
The US government has ambitious goals to expand the number of people tested and treated for HIV in the coming years. A new study details the best interventions to make the biggest difference for the most people.
What "Ending the HIV Epidemic" Entails
Ian Frank, MD, explains the "Ending the Epidemic" initiative.
